47 related articles for article (PubMed ID: 10426152)
21. Genetic association studies of tumour necrosis factor alpha and beta and tumour necrosis factor receptor 1 and 2 polymorphisms across the clinical spectrum of multiple sclerosis.
McDonnell GV; Kirk CW; Middleton D; Droogan AG; Hawkins SA; Patterson CC; Graham CA
J Neurol; 1999 Nov; 246(11):1051-8. PubMed ID: 10631637
[TBL] [Abstract][Full Text] [Related]
22. Lack of association of transforming growth factor (TGF)-beta 1 and beta 2 gene polymorphisms with multiple sclerosis (MS) in Northern Ireland.
McDonnell GV; Kirk CW; Hawkins SA; Graham CA
Mult Scler; 1999 Apr; 5(2):105-9. PubMed ID: 10335519
[TBL] [Abstract][Full Text] [Related]
23. Analysis of interleukin-4 receptor alpha chain variants in multiple sclerosis.
Hackstein H; Bitsch A; Bohnert A; Hofmann H; Weber F; Ohly A; Linington C; Mäurer M; Poser S; Rieckmann P; Bein G
J Neuroimmunol; 2001 Feb; 113(2):240-8. PubMed ID: 11164908
[TBL] [Abstract][Full Text] [Related]
24. The role of HLA-DRB1 alleles on susceptibility and outcome of a Portuguese Multiple Sclerosis population.
Silva AM; Pereira C; Bettencourt A; Carvalho C; Couto AR; Leite MI; Marta M; Freijo M; Costa PP; Mendonça D; Monteiro L; Armas JB; Martins B
J Neurol Sci; 2007 Jul; 258(1-2):69-74. PubMed ID: 17412364
[TBL] [Abstract][Full Text] [Related]
25. Combined effect of HLA-DRB1*1501 and interleukin-1 receptor antagonist gene allele 2 in susceptibility to relapsing/remitting multiple sclerosis.
de la Concha EG; Arroyo R; Crusius JB; Campillo JA; Martin C; Varela de Seijas E; Peña AS; Clavería LE; Fernandez-Arquero M
J Neuroimmunol; 1997 Dec; 80(1-2):172-8. PubMed ID: 9413274
[TBL] [Abstract][Full Text] [Related]
26. A study of the HLA-DR region in clinical subgroups of multiple sclerosis and its influence on prognosis.
McDonnell GV; Mawhinney H; Graham CA; Hawkins SA; Middleton D
J Neurol Sci; 1999 May; 165(1):77-83. PubMed ID: 10426152
[TBL] [Abstract][Full Text] [Related]
27. HLA and multiple sclerosis in Italy: a review of the literature.
La Mantia L; Illeni MT; Milanese C; Salmaggi A; Eoli M; Pellegris G; Nespolo A
J Neurol; 1990 Nov; 237(7):441-4. PubMed ID: 2273414
[TBL] [Abstract][Full Text] [Related]
28. Natural history of primary progressive multiple sclerosis.
Ebers GC
Mult Scler; 2004 Jun; 10 Suppl 1():S8-13; discussion S13-5. PubMed ID: 15218804
[TBL] [Abstract][Full Text] [Related]
29. Disease-Modifying Treatment in Progressive Multiple Sclerosis.
Ciotti JR; Cross AH
Curr Treat Options Neurol; 2018 Apr; 20(5):12. PubMed ID: 29627873
[TBL] [Abstract][Full Text] [Related]
30. Genetic analysis of the exon 1 position 49 CD152 dimorphism in multiple sclerosis.
Stuart R; Lovett-Racke AE; Frohman EM; Hawker K; Racke MK
J Neuroimmunol; 2007 Nov; 191(1-2):45-50. PubMed ID: 17920697
[TBL] [Abstract][Full Text] [Related]
31. Highly active multiple sclerosis: An update.
Díaz C; Zarco LA; Rivera DM
Mult Scler Relat Disord; 2019 May; 30():215-224. PubMed ID: 30822617
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic Advances and Challenges in the Treatment of Progressive Multiple Sclerosis.
Baldassari LE; Fox RJ
Drugs; 2018 Oct; 78(15):1549-1566. PubMed ID: 30255442
[TBL] [Abstract][Full Text] [Related]
33. MicroRNAs, Multiple Sclerosis, and Depression.
Wang H
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360568
[TBL] [Abstract][Full Text] [Related]
34. Identifying disease modifying genes in multiple sclerosis.
Kantarci OH; de Andrade M; Weinshenker BG
J Neuroimmunol; 2002 Feb; 123(1-2):144-59. PubMed ID: 11880159
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
